Studies demonstrated the CATS Prism improves IOP accuracy by 94% over the GAT for this patient population. On a world-wide basis, the CATS Prism provides the eye care clinician the sight-saving IOP data required to properly diagnose and treat glaucoma and other ocular related diseases for their patients.
Since intraocular eye pressure (IOP) is a critical metric for assessing the ocular health of a patient, our CATS Tonometer Prism™ has the potential to greatly enhance clinical care through increased accuracy related to IOP measurements. The reusable version of the CATS Tonometer Prism™ has been cleared by the FDA for sale in the United States. Measurement of IOP is not only critical to the accurate diagnosis of ocular disease but also a necessary guide to effective treatment strategies. The CATS Tonometer Prism™ is designed to enhance IOP measurements through an easily adopted modification to the surface of the GAT prism. Additionally, the CATS Tonometer Prism™ is designed to be easily implemented by the worldwide eye care community without altering existing practitioner protocols and with minimal costs related to only changing the GAT’s tip.
Five scientific studies demonstrated the clinical performance of the CATS™ prism in comparison to the GAT prism. The peer-reviewed publications included a direct comparison to the existing GAT prism; human cadaver eye intracameral pressure transducer comparison of the CATS and GAT; an actual intracamerally placed pressure transducer comparison of the CATS and GAT in live human eyes, and tear-film hydrostatic study. All five studies confirmed our original mathematical modeling design predictions developed in a National Institute of Health, SBIR Phase I grant. IOP measurement for pediatric patients and post-corneal refractive surgery patients (LASIK, PRK, SMILE, and RK) are well-known to be highly inaccurate and might benefit from the CATS prism’s improved IOP accuracy. Further testing in these populations with the CATS Tonometer is required to examine the prism’s full potential. Our presentation on this topic won “Best Paper of Session” at the 2018 and 2015 American Society of Cataract and Refractive Surgery (ASCRS) Conference. Additionally, presentations were also made at the:
The CATS Tonometer Prism™ is FDA cleared for marketing and sale in the United States and we are in the process of securing the CE Mark.
Dr. McCafferty founded Intuor Technologies, LLC and serves as the Chief Executive Officer. He possesses solid expertise in mechanical engineering, optical engineering, and optical engineering, and ophthalmology coupled with demonstrated entrepreneurial skills. This depth of understanding in all three fields is critical to producing products with a wide variety of optical and ophthalmic applications. After completing his undergraduate degree in mechanical engineering, he worked as a product development engineer developing ideas, patents, and profitable products. He then attended the Ohio State University’s Medical School and subsequently completed a residency in ophthalmology at the University of Arizona.
Following residency, Dr. McCafferty became a serial entrepreneur and business manager founding very successful enterprises such as Arizona Eye Consultants, Camp Lowell Surgery Center, Carondelet Foothills Surgery Center, and Intuor Technologies, LLC. Simultaneously, he completed a Master of Science (MS) degree in optical engineering at the University of Arizona expressly to allow his ideas to become reality in the form of products for the ophthalmic industry. During his optical engineering education, Dr. McCafferty’s ophthalmic opto-mechanics research was self-directed under the mentorship of Jim Schwiegerling, Ph.D. He authored several peer-reviewed articles and papers on the subject. In 2017 the University of Arizona Alumni Association selected Dr. McCafferty as the 2017 Alumnus of the Year for the College of Optical Sciences. Click here to see a listing of his publications. Additionally, Dr. McCafferty has produced 10 patents or published patent applications on ophthalmic opto-mechanics.
Nannon Roosa leads the operational and financial functions for Intuor Technologies. She achieves organizational goals through successful execution of business strategies. Leveraging project management skills, she directs short-term and long-range strategic planning, intellectual property, and budgeting processes. Ms. Roosa guides and participates in growth activities and investor relations to support overall business objectives and plans. Good Clinical Practice (GCP) trained, she also participates in monitoring activities related to scientific studies.
Ms. Roosa’s unique skill set results from her career that includes a wide range of consulting and entrepreneurial endeavors. Ms. Roosa has 25 years of experience providing client services and business development activities with PricewaterhouseCoopers, KPMG, and Clifton Gunderson. Her positions with these companies ranged from identifying client needs, driving new products to market, managing key client relationships, and client service. Most recently, Ms. Roosa was the University of Arizona’s Director for MBA Experiential Learning, where she led the MBA Consulting Program. Under her tenure, Ms. Roosa executed 97 successful projects for clients in the technology and healthcare sectors.
Ms. Roosa is a Project Management Professional (PMP), Certified Public Accountant (CPA), Certified Financial Planner (CFP©), and a Certified Medical Practice Executive (CMPE) designation from the MGMA, or Medical Group Management Association. She earned a B.S. in Business Administration (Major – Accounting) from the University of Tennessee and a Masters in Tax from the University of Texas at San Antonio.
William Lomicka has more than four decades of healthcare financial management and venture capital experience. Over the years, he has served as a director or senior leader for several U.S. healthcare companies, including health insurance, hospital management, medical device companies, acute care hospitals, nursing and assisted living facilities, and healthcare technology firms. As Senior Vice President of Finance for Humana, Inc., Mr. Lomicka planned, developed, and implemented financial strategies and controls, which generated revenue growth from $145 million to $3 billion. Following Humana, he worked for a healthcare venture capital firm in New York City, where he developed and managed healthcare investments. Mr. Lomicka also served as Secretary of Economic Development for the Commonwealth of Kentucky, later forming a private investment firm in Louisville specializing in venture capital.
Mr. Lomicka currently serves as Chairman of Coulter Ridge Capital and presently serves on the boards of numerous companies, both public and private. He also serves on numerous service boards including the Board of Heuser Hearing Institute in Louisville and Chairs the Board of the Arizona Sonora Desert Museum in Tucson, Arizona.
He earned his MBA from the Wharton School at the University of Pennsylvania after completing his undergraduate degree from Wooster College.
Mr. Lang has three decades of experience in large scale contract manufacturing, and his business expanded into a multi-national operation (US, Mexico, and China) via acquisition of off-shore manufacturing business, development of integrated and cross-enterprise information & financial accounting systems. He currently serves as a Senior Advisor and Consultant to Integrated Cable Assembly Holdings, Inc. and has C-level experience with executive management experience as CEO, COO, CFO & CTO of companies from $10MM to $200MM turnover.
Dr. John Berdahl specializes in advanced cataract surgery, corneal surgery, and glaucoma surgery at Vance Thompson Vision. Dr. Berdahl is a recognized world leader for the advancement of glaucoma treatment. He’s been recognized by the American Medical Association as the Top Young Physician in South Dakota and was awarded the national Claes Dohlman Award by Harvard for being the most outstanding cornea fellow in 2008 and identified as one of the top 40 under 40 ophthalmologists worldwide
Dr. Radcliffe, Mt. Sinai School of Medicine, is a glaucoma and cataract surgeon who specializes in the fields of corneal biomechanics, micro incisional glaucoma surgery, and glaucoma pharmacotherapy. He is the Chief Editor of the publication Glaucoma Physician and the Glaucoma Section Editor of Eyeworld Magazine and is on the ASCRS glaucoma program committee. Dr. Radcliffe is passionate about peer to peer education and innovation and blends academic science to elevate private practice clinical medicine.
Dr. Jim Schwiegerling is a Professor of Optical Sciences and Ophthalmology and Vision Sciences at the University of Arizona and an integral part of our team. His expertise is in design and development of ophthalmic diagnostic equipment and the modeling of visual performance. Dr. Schweigerling received Career Development and Innovative Ophthalmic Research awards from Research to Prevent Blindness and holds two patents with two additional patents pending. Dr. Schwiegerling is widely published in the fields of optical science and ophthalmic optics.
Mr. Heck has over 25 years of diverse experience in the eye care field serving in several executive positions. His career management responsibilities included sales, marketing, finance, product management, business development and medical device manufacturing. Mr. Heck most recently managed Wilson Ophthalmic Corporation, a distributor of eye care specific pharmaceuticals and medical devices as the Director of Operations, and he currently consults for several medical device companies.
Mr. Soiseth has 20 years of experience in the design, development, manufacturing, and testing of advanced optical and ophthalmic devices, and he also has15 years of experience with the same aspects of electro-mechanical equipment. This experience has provided him with direct experience to be very efficient in the development of ophthalmic equipment and systems. Mr. Soiseth is a hands-on engineer with many engineering and software tools available to him, all of which contribute to his ability to move from initial design to final, built devices or systems. He was an Engineering Director with Bausch+Lomb and Eyeonics.
Mr. Kramsky has four decades years of medical device industry regulatory expertise (US and international), prior VP with Bausch+Lomb and Eyeonics. Mr. Kransky has amassed specialized knowledge and experience with ophthalmic surgical implants, instruments, and durable equipment. He is also experienced with IDEs, PMAs, 510(k)s, international registrations, quality systems certification (e.g., ISO 13485), CE Marking, and CMDCAS registration.
Dr. Khodai has provided more than 20 years expert scientific clinical development advice and leadership for all phases of the clinical programs. He assists in the development of clinical study strategy strategies and reviews clinical protocols and clinical study reports for scientific and operational accuracy.
Dr. Eniko T. Enikov is an Associate Professor, BIO5 (UA 5 college collaboration) and Aerospace & Mechanical Engineering at the University of Arizona a research focus in ocular tonometry, biological imaging, biomaterials, biophysics, and bioengineering. In addition to receiving a Fulbright Fellowship and National Science Foundation Career Award, Dr. Enikov holds four patents and has received 15 research grants since 2004.
Tim Nieman is founder and CEO of ZIEN Medical Technologies (www.zienmedical.com). He holds a BS in Bioengineering from Arizona State University and has over 23 years experience as a medical device professional and entrepreneur. As an entrepreneur and founder of ZIEN, Tim and his team are currently participating in the success and growth of numerous businesses and expanded to serve companies internationally.
CATS Tonometer, LLC routinely shares the results of our scientific studies with the clinician community at conferences and other venues. We also share our knowledge and experiences with a variety of groups in support of science, technology, engineering, and math (STEM) disciplines.Events
Since intraocular eye pressure (IOP) is a critical metric for assessing the ocular health of a patient, our CATS Tonometer Prism™ has the potential to greatly enhance clinical care through a reduction in errors related to IOP measurements. The reusable version of the CATS Tonometer Prism™ has been cleared by the FDA for sale in the United States. Measurement of IOP is not only critical to the accurate diagnosis of ocular disease, but is also a necessary guide to effective treatment strategies. The CATS Tonometer Prism™ is designed to enhance IOP measurements through an easily adopted modification to the surface of the GAT prism. Additionally, the CATS Tonometer Prism™ is designed to be easily implemented by the worldwide eye care community without altering existing practitioner protocols and with minimal costs related to only changing the GAT’s tip.
Five scientific studies demonstrated the clinical performance of the CATS™ prism in comparison to the GAT prism. The peer-reviewed publications included a direct comparison to the existing GAT prism; human cadaver eye intracameral pressure transducer comparison of the CATS and GAT; an actual intracamerally placed pressure transducer comparison of the CATS and GAT in live human eyes, and tear-film hydrostatic study. All five studies confirmed our original mathematical modeling design predictions developed in a National Institute of Health, SBIR Phase I grant. Additionally, subgroups of pediatric patients and post-refractive (LASIK, PRK, SMILE, and RK) surgery patients - which combined represent 30% of the U.S. population - exhibit clinically relevant GAT errors in more than 50% of patients. Further testing in these populations with the CATS Tonometer is required to examine the prism’s full potential. Our presentation on this topic won “Best Paper of Session” at the 2015 American Society of Cataract and Refractive Surgery (ASCRS) Conference. Additionally, presentations were also made at the 2017 ASCRS Annual Meeting, Los Angeles, May 7th, and the Association for Research in Vision and Ophthalmology (ARVO) Annual Conference, Baltimore, May 8th. We are scheduled to deliver presentations in 2018 at the American Glaucoma Society Annual Meeting in New York in March, the ASCRS Annual Meeting in Washington DC April 2018, and the ARVO Annual Conference in Hawaii in April 2018.
The CATS Tonometer Prism™ is FDA cleared for marketing and sale in the United States and we are in the process of securing the CE Mark.
The intellectual property of CATS Tonometer LLC is protected by the following patents and Certificates of Registration. Additionally, there are various pending US and foreign patent applications.